Last reviewed · How we verify
Co-trimoxazole 20
Co-trimoxazole is a fixed-dose combination of sulfamethoxazole and trimethoprim that inhibits bacterial folate synthesis at two sequential steps, preventing DNA replication.
Co-trimoxazole is a fixed-dose combination of sulfamethoxazole and trimethoprim that inhibits bacterial folate synthesis at two sequential steps, preventing DNA replication. Used for Urinary tract infections, Respiratory tract infections, Otitis media.
At a glance
| Generic name | Co-trimoxazole 20 |
|---|---|
| Sponsor | Khon Kaen University |
| Drug class | Sulfonamide antibiotic combination |
| Target | Dihydropteroate synthase and dihydrofolate reductase |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Sulfamethoxazole inhibits dihydropteroate synthase, while trimethoprim inhibits dihydrofolate reductase. Together, they block the bacterial synthesis of dihydrofolate and tetrahydrofolate, nucleotides essential for DNA synthesis. This synergistic dual inhibition is bactericidal and provides broad-spectrum coverage against many gram-positive and gram-negative organisms.
Approved indications
- Urinary tract infections
- Respiratory tract infections
- Otitis media
- Pneumocystis jirovecii pneumonia (PCP) prophylaxis and treatment
- Toxoplasmosis
Common side effects
- Rash
- Nausea
- Vomiting
- Diarrhea
- Hyperkalemia
- Stevens-Johnson syndrome
- Hepatotoxicity
Key clinical trials
- Testing a Novel Combination Treatment (Arm D) Versus Standard of Care for Intensive Phase Treatment for Mycobacterium Abscessus Pulmonary Disease in People With or Without Cystic Fibrosis in the Finding the Optimal Regimen for Mycobacterium Abscessus Treatment (FORMaT) Adaptive Platform Trial (PHASE2)
- Effects of Treatments on Atopic Dermatitis (PHASE2)
- Comparative Efficacy of Antibiotics for Small Intestine Bacterial Overgrowth in Bangladeshi Children (PHASE2)
- 3-day IV Antibiotic Treatment Versus 3-day IV Followed by 7-day Oral Antibiotic Treatment for AP in Children (PHASE4)
- Empirical Treatment Against Cytomegalovirus and Tuberculosis in HIV-infected Infants With Severe Pneumonia (PHASE2, PHASE3)
- Finding the Optimal Regimen for Mycobacterium Abscessus Treatment (PHASE2, PHASE3)
- Rezafungin for Treatment of Pneumocystis Pneumonia in HIV Adults (PHASE2)
- Dexamethasone for Cerebral Toxoplasmosis (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Co-trimoxazole 20 CI brief — competitive landscape report
- Co-trimoxazole 20 updates RSS · CI watch RSS
- Khon Kaen University portfolio CI